Johnson & Johnson (JNJ)
Johnson & Johnson: Market Will Regret The Overreaction
Johnson & Johnson stock prices have been consistently declining in the recent 1~2 years. The stock is currently undervalued, with lower P/E ratios compared to the sector median and historical averages, and a high dividend yield. Yet, Johnson & Johnson's profitability remains strong, and there are potential catalysts for growth, including the adoption of new products and potential acquisitions.
Boring Is Beautiful: 3 Blue-Chip Stocks to Buy and Hold Forever
As someone who has been actively investing for several years, I can tell you that it's natural to be drawn to thrilling investment opportunities promising impressive returns. However, I've learned that while the appeal of these opportunities is strong, embracing the stability of “boring” stocks often proves to be the wiser course of action.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $145.28, moving +0.58% from the previous trading session.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)
Johnson & Johnson (NYSE:JNJ ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
J&J's treatment for depression succeeds in late stage study
Johnson & Johnson said on Wednesday its experimental therapy, seltorexant, met all main and secondary goals in a late-stage study evaluating it in patients with major depressive disorder (MDD) and insomnia symptoms.
J&J acquires rights to skin disorder drug for $1.25 bln
Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $146.97, denoting a -1.82% change from the preceding trading day.
3 Stocks to Safeguard Your Investments During a Market Meltdown
In today's uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty.
